Dorothy Margolskee
Managing Director @ Foresite Capital
Voorhees, United States
Dorothy Margolskee is a Series C investor at Foresite Capital in Voorhees focused on Medical and Health Care. Dorothy Margolskee is based out of Voorhees, New Jersey and is the Managing Director of Foresite Capital Management. Dorothy previously worked at Prospect Venture Partners as a Senior Advisor. Dorothy Margolskee attended The Johns Hopkins University School of Medicine. Dorothy has received an MRL Divisional Scientific Award.
- Total investments:
- 1
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Dorothy Margolskee invests in
Stages Dorothy Margolskee invests in
Countries Dorothy Margolskee invests in
Investment Focus
Industry
- Medical 1 (100%)
- Health Care 1 (100%)
- Biotechnology 1 (100%)
- Pharmaceutical 1 (100%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
|
|
Affinivax is a biopharmaceutical company developing vaccines used to enhance the depth of protection against infectious diseases.This novel and highly efficient vaccine conjugation technology – named MAPS for Multiple Antigen Presenting System – has the potential to deliver novel vaccines that offer broader disease coverage than existingvaccines, as well as protect against infectious diseases for which there are no effective immunization strategies today.The company is rapidly advancing a lead program targeting Streptococcus pneumoniae (pneumococcus), a pathogen that is responsible for significant morbidity and mortality in children and adults worldwide. Affinivax was established based on the knowledge and insights of world-leading experts in the fields of infectious diseases and vaccines. The company is backed by an investment from the Bill & Melinda Gates Foundation and has an exclusive license from Boston Children’s Hospital for intellectual property related to the MAPS technology platform. | $226M / Series C / Jan 08, 2021 |
Co-Investors
About Foresite Capital
Foresite Capital is a healthcare and life sciences investment firm. They take a data-driven approach to invest in startups that employ biology and big data to improve healthcare, such as 10x Genomics, Relay Therapeutics, Element Biosciences, and Inscripta.
Foresite Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Dorothy Margolskee
Managing Director
|
|||
|
James Tananbaum
Founder and CEO
|
|||
|
Stephen C. Peterson
Partner
|
|||
|
Dennis D. Ryan
CFO & Managing Director
|
|||
|
Elizabeth Liz Canis
Senior Advisor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Dorothy Margolskee invest in?
Dorothy Margolskee invests primarily in Medical, Health Care and Biotechnology startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Dorothy Margolskee last invest?
The most recent investment recorded for Dorothy Margolskee closed in Jan 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!